Replies to post #60861 on Biotech Values

[DewDiligence]

>…the former [Tyzeka] is widely perceived to be an inferior agent in the marketplace…<

Quite so; however, Recothrom is widely perceived to solve a problem that surgeons didn’t even know they had.

>baraclude had pathetic us sales at launch (7M in its first 6 months!)<

The way things appear to be going, you may need some luck to get to $7M of Recothrom sales in the same period.